top of page

Market Research Group

Public·35 members
Aslan Korolev
Aslan Korolev

Invion Gps 4v223 Iit Update

The company launched its second PDT compound, INV-163, in 2015. In June of 2018, Invion announced an exclusive worldwide license agreement for the development and commercialization of INV-163 and its successors by Invion for the treatment of various cancers, including melanoma, ovarian, breast, prostate and lung, under an accelerated development and regulatory pathway.

invion gps 4v223 iit update

The value of having a unique, proprietary, and a uniquely-delivery system is the ability to customize the delivery of the drug to each patient, to help them reach their full therapeutic potential. So far, Invion has completed INDs for the first two devices with a third underway.

At the present, Invion has more than 50 INDs for PDT in the preclinical or clinical phases of development. Each of them is in an advanced stage. Invion is now beginning to launch their products to global markets. In October 2017, Invion launched INV-203, a soft capsule to be used as an adjuvant to chemotherapy for metastatic breast cancer. This product is believed to extend the lives of patients by improving the efficacy of the chemo and reducing the likelihood of the cancer returning. INV-203 is currently in Phase II clinical trials.

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the companys ability to generate profit. But as Invion has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.


Welcome to the group! You can connect with other members, ge...


bottom of page